The study of ST-1891 vs. Levothyroxine in patients with primary hypothyroidism

 

The company Sention Therapeutics, LLC is enrolling patients into the clinical trial investigating Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism.

ST-1891 is a multicenter, randomized, double-blind, crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary hypothyroidism.

The trial is designed to enroll male and female 18 Years to 75 Years and is being conducted in several location in the USA; study start date is April 29, 2022.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05412979 or https://clinicaltrials.gov/NCT05412979.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

The study of ST-1891 vs. Levothyroxine in patients with primary hypothyroidism

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe